Skip to main content

Advertisement

Table 1 The baseline and clinicopathologic characteristics of 184 patients with metastatic renal cell carcinoma

From: Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma

Variable No. of patients (%) Post-treatment hypoalbuminemia group (<36.4 g/L) Normal post-treatment albumin level group (≥36.4 g/L) P value
Sex     0.589
 Men 137 (74.5) 27 (71.1) 110 (75.3)  
 Women 47 (25.5) 11 (28.9) 36 (24.7)  
Age (years)     0.215
 <65 141 (76.6) 32 (84.2) 109 (74.7)  
 ≥65 43 (23.4) 6 (15.8) 37 (25.3)  
Pathologic type     0.060
 ccRCC 179 (97.3) 35 (92.1) 144 (98.6)  
 nccRCC 5 (2.7) 3 (7.9) 2 (1.4)  
History of nephrectomy     0.945
 Yes 146 (79.3) 30 (79.0) 116 (79.5)  
 No 38 (20.7) 8 (21.0) 30 (20.5)  
History of cytokine treatment     0.811
 Yes 66 (35.9) 13 (34.2) 53 (36.3)  
 No 118 (64.1) 25 (65.8) 93 (63.7)  
Fuhrman grade     <0.001
 1–2 104 (56.5) 9 (23.7) 95 (65.1)  
 3–4 65 (35.3) 24 (63.2) 41 (28.1)  
 Unknown 15 (8.2) 5 (13.1) 10 (6.8)  
Number of metastatic sites     0.053
 1 130 (70.7) 22 (57.9) 108 (74.0)  
 ≥2 54 (29.3) 16 (42.1) 38 (26.0)  
Metastatic site     
 Lung 137 (74.5) 33 (86.8) 104 (71.2) 0.050
 Lymph node 44 (23.9) 11 (29.0) 33 (22.6) 0.414
 Bone 20 (10.9) 0 (0.0) 20 (13.7) 0.034
 Liver 16 (8.7) 2 (5.3) 14 (9.6) 0.400
 Others 15 (8.2) 2 (5.3) 13 (8.9) 0.465
MSKCC risk category     0.072
 Favorable 83 (45.1) 12 (31.6) 71 (48.6)  
 Intermediate 72 (39.1) 18 (47.4) 54 (37.0)  
 Poor 29 (15.8) 8 (21.0) 21(14.4)  
NLR     0.440
 <2.2 73 (39.7) 13 (34.2) 60 (41.1)  
 ≥2.2 111 (60.3) 25 (65.8) 86 (58.9)  
First-line therapy     0.149
 Sorafenib 112 (60.9) 27 (71.1) 85 (58.2)  
 Sunitinib 72 (39.1) 11 (28.9) 61 (41.8)  
  1. ccRCC, clear cell renal cell carcinoma; nccRCC, non-clear cell renal cell carcinoma; MSKCC, Memorial Sloan Kettering Cancer Center; NLR, neutrophil-to-lymphocyte ratio